Panavance Therapeutics

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

BERWYN, PA — Panavance Therapeutics Inc. announced the recent publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript titled, “GP-2250, a novel anticancer agent, …

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer Read More

Cancer

New Research for Borderline Resectable Locally Advanced Pancreatic Cancer Patients

PLYMOUTH MEETING, PA — New research in the September 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic …

New Research for Borderline Resectable Locally Advanced Pancreatic Cancer Patients Read More